

Oncology Today with Dr Neil Love: Advances in the Management of Amyloid Light Chain Amyloidosis

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The ANDROMEDA study, evaluating the addition of subcutaneous daratumumab to CyBORd (cyclophosphamide/bortezomib/dexamethasone) for patients with newly diagnosed AL amyloidosis, reported an improvement in which of the following outcomes with daratumumab?**
 - a. Major organ deterioration progression-free survival (MOD-PFS) only
 - b. Overall complete hematologic response rate (CHR) only
 - c. Both MOD-PFS and CHR**
- 2. Which of the following drug types best reflects the mechanism of action of CAEL-101, under investigation for AL amyloidosis?**
 - a. IMiD (immunomodulatory drug)
 - b. Bcl-2 inhibitor
 - c. Antibody targeting light chain amyloid fibrils**
- 3. Which of the following statements is FALSE about the t(11;14) translocation in AL amyloidosis?**
 - a. Patients with the translocation respond to bortezomib as well as do patients without the translocation**
 - b. Patients with relapsed/refractory t(11;14) disease experience deep responses to venetoclax
 - c. The translocation occurs in about 50% of patients with AL amyloidosis
- 4. Which of the following symptoms has been associated with AL amyloidosis?**
 - a. Unexplained weight loss only
 - b. Shortness of breath only
 - c. Peripheral neuropathy only
 - d. All of the above**